Discontinuation of Secondary Prophylaxis for Cryptococcal Meningitis in Human Immunodeficiency Virus–Infected Patients Treated with Highly Active Antiretroviral Therapy: A Prospective, Multicenter, Randomized Study | Zendy

Asda Vibhagool | Zendy; Somnuek Sungkanuparph | Zendy; Piroon Mootsikapun | Zendy; Ploenchan Chetchotisakd | Zendy; Somsit Tansuphaswaswadikul | Zendy; Chureeratana Bowonwatanuwong | Zendy; Atiporn Ingsathit | Zendy

Open Access

Discontinuation of Secondary Prophylaxis for Cryptococcal Meningitis in Human Immunodeficiency Virus–Infected Patients Treated with Highly Active Antiretroviral Therapy: A Prospective, Multicenter, Randomized Study

Author(s) -

Asda Vibhagool,

Somnuek Sungkanuparph,

Piroon Mootsikapun,

Ploenchan Chetchotisakd,

Somsit Tansuphaswaswadikul,

Chureeratana Bowonwatanuwong,

Atiporn Ingsathit

Publication year - 2003

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/374849

Subject(s) - medicine , discontinuation , randomized controlled trial , meningitis , randomization , secondary prophylaxis , multicenter trial , prospective cohort study , sida , viral disease , human immunodeficiency virus (hiv) , immunology , pediatrics , multicenter study

A prospective, multicenter, randomized study was conducted with human immunodeficiency virus (HIV)-infected patients who were successfully treated for acute cryptococcal meningitis, were receiving secondary prophylaxis, and were naive for antiretroviral therapy. Patients were randomized to continue or discontinue secondary prophylaxis when the CD4 cell count had increased to >100 cells/microL and an undetectable HIV RNA level had been sustained for 3 months. At a median of 48 weeks after randomization, there were no episodes of cryptococcal meningitis in either group.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research